vs
Custom Truck One Source, Inc.（CTOS）与UNITED THERAPEUTICS Corp（UTHR）财务数据对比。点击上方公司名可切换其他公司
UNITED THERAPEUTICS Corp的季度营收约是Custom Truck One Source, Inc.的1.7倍（$790.2M vs $461.6M），UNITED THERAPEUTICS Corp净利率更高（46.1% vs -0.9%，领先47.0%），UNITED THERAPEUTICS Corp同比增速更快（7.4% vs -12.6%），过去两年Custom Truck One Source, Inc.的营收复合增速更高（20.0% vs 8.0%）
Custom Truck One Source是北美领先的专用重型卡车及设备解决方案提供商，业务覆盖定制车辆制造、设备销售与租赁、售后配件供应及维保服务，主要服务基建、公用事业、建筑、能源等核心领域。
United Therapeutics是美国生物技术企业，专注开发包含异种移植在内的器官移植相关药物与技术，多款产品布局肺部疾病及器官制造赛道，双总部位于马里兰州银泉与北卡罗来纳州三角研究园，在美加多地设有研发及运营分支机构。
CTOS vs UTHR — 直观对比
营收规模更大
UTHR
是对方的1.7倍
$461.6M
营收增速更快
UTHR
高出20.0%
-12.6%
净利率更高
UTHR
高出47.0%
-0.9%
两年增速更快
CTOS
近两年复合增速
8.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $461.6M | $790.2M |
| 净利润 | $-4.1M | $364.3M |
| 毛利率 | 22.3% | 86.9% |
| 营业利润率 | 6.8% | 45.1% |
| 净利率 | -0.9% | 46.1% |
| 营收同比 | -12.6% | 7.4% |
| 净利润同比 | 76.9% | 20.9% |
| 每股收益（稀释后） | $-0.02 | $7.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTOSUTHR
| Q1 26 | $461.6M | — | ||
| Q4 25 | $387.3M | $790.2M | ||
| Q3 25 | $359.9M | $799.5M | ||
| Q2 25 | $392.2M | $798.6M | ||
| Q1 25 | $307.1M | $794.4M | ||
| Q4 24 | $398.3M | $735.9M | ||
| Q3 24 | $337.5M | $748.9M | ||
| Q2 24 | $320.6M | $714.9M |
净利润CTOSUTHR
| Q1 26 | $-4.1M | — | ||
| Q4 25 | $20.9M | $364.3M | ||
| Q3 25 | $-5.8M | $338.7M | ||
| Q2 25 | $-28.4M | $309.5M | ||
| Q1 25 | $-17.8M | $322.2M | ||
| Q4 24 | $27.6M | $301.3M | ||
| Q3 24 | $-17.4M | $309.1M | ||
| Q2 24 | $-24.5M | $278.1M |
毛利率CTOSUTHR
| Q1 26 | 22.3% | — | ||
| Q4 25 | 31.8% | 86.9% | ||
| Q3 25 | 28.0% | 87.4% | ||
| Q2 25 | 26.1% | 89.0% | ||
| Q1 25 | 27.9% | 88.4% | ||
| Q4 24 | 29.7% | 89.7% | ||
| Q3 24 | 27.2% | 88.9% | ||
| Q2 24 | 27.8% | 89.1% |
营业利润率CTOSUTHR
| Q1 26 | 6.8% | — | ||
| Q4 25 | 13.4% | 45.1% | ||
| Q3 25 | 9.1% | 48.6% | ||
| Q2 25 | 7.1% | 45.6% | ||
| Q1 25 | 4.0% | 48.2% | ||
| Q4 24 | 16.9% | 48.6% | ||
| Q3 24 | 6.8% | 45.8% | ||
| Q2 24 | 5.5% | 44.7% |
净利率CTOSUTHR
| Q1 26 | -0.9% | — | ||
| Q4 25 | 5.4% | 46.1% | ||
| Q3 25 | -1.6% | 42.4% | ||
| Q2 25 | -7.2% | 38.8% | ||
| Q1 25 | -5.8% | 40.6% | ||
| Q4 24 | 6.9% | 40.9% | ||
| Q3 24 | -5.2% | 41.3% | ||
| Q2 24 | -7.6% | 38.9% |
每股收益（稀释后）CTOSUTHR
| Q1 26 | $-0.02 | — | ||
| Q4 25 | $0.10 | $7.66 | ||
| Q3 25 | $-0.03 | $7.16 | ||
| Q2 25 | $-0.13 | $6.41 | ||
| Q1 25 | $-0.08 | $6.63 | ||
| Q4 24 | $0.11 | $6.23 | ||
| Q3 24 | $-0.07 | $6.39 | ||
| Q2 24 | $-0.10 | $5.85 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.6M | $2.9B |
| 总债务越低越好 | $5.1M | — |
| 股东权益账面价值 | $805.2M | $7.1B |
| 总资产 | $3.5B | $7.9B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资CTOSUTHR
| Q1 26 | $9.6M | — | ||
| Q4 25 | $6.3M | $2.9B | ||
| Q3 25 | $13.1M | $2.8B | ||
| Q2 25 | $5.3M | $3.0B | ||
| Q1 25 | $5.4M | $3.3B | ||
| Q4 24 | $3.8M | $3.3B | ||
| Q3 24 | $8.4M | $3.3B | ||
| Q2 24 | $8.1M | $3.0B |
总债务CTOSUTHR
| Q1 26 | $5.1M | — | ||
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.5B | — |
股东权益CTOSUTHR
| Q1 26 | $805.2M | — | ||
| Q4 25 | $809.1M | $7.1B | ||
| Q3 25 | $784.7M | $6.6B | ||
| Q2 25 | $790.1M | $7.2B | ||
| Q1 25 | $813.4M | $6.8B | ||
| Q4 24 | $861.3M | $6.4B | ||
| Q3 24 | $837.5M | $6.1B | ||
| Q2 24 | $856.7M | $5.7B |
总资产CTOSUTHR
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.4B | $7.9B | ||
| Q3 25 | $3.5B | $7.4B | ||
| Q2 25 | $3.6B | $7.9B | ||
| Q1 25 | $3.5B | $7.7B | ||
| Q4 24 | $3.5B | $7.4B | ||
| Q3 24 | $3.6B | $7.1B | ||
| Q2 24 | $3.5B | $6.7B |
负债/权益比CTOSUTHR
| Q1 26 | 0.01× | — | ||
| Q4 25 | 2.03× | — | ||
| Q3 25 | 2.10× | — | ||
| Q2 25 | 2.04× | — | ||
| Q1 25 | 1.97× | — | ||
| Q4 24 | 1.77× | — | ||
| Q3 24 | 1.87× | — | ||
| Q2 24 | 1.79× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $346.2M |
| 自由现金流经营现金流 - 资本支出 | — | $173.3M |
| 自由现金流率自由现金流/营收 | — | 21.9% |
| 资本支出强度资本支出/营收 | — | 21.9% |
| 现金转化率经营现金流/净利润 | — | 0.95× |
| 过去12个月自由现金流最近4个季度 | — | $1.0B |
8季度趋势，按日历期对齐
经营现金流CTOSUTHR
| Q1 26 | — | — | ||
| Q4 25 | $47.3M | $346.2M | ||
| Q3 25 | $81.5M | $562.1M | ||
| Q2 25 | $125.7M | $191.7M | ||
| Q1 25 | $55.6M | $461.2M | ||
| Q4 24 | $82.1M | $341.2M | ||
| Q3 24 | $16.5M | $377.2M | ||
| Q2 24 | $37.8M | $232.2M |
自由现金流CTOSUTHR
| Q1 26 | — | — | ||
| Q4 25 | — | $173.3M | ||
| Q3 25 | — | $351.6M | ||
| Q2 25 | — | $129.5M | ||
| Q1 25 | — | $386.3M | ||
| Q4 24 | — | $254.5M | ||
| Q3 24 | — | $300.7M | ||
| Q2 24 | — | $187.1M |
自由现金流率CTOSUTHR
| Q1 26 | — | — | ||
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 44.0% | ||
| Q2 25 | — | 16.2% | ||
| Q1 25 | — | 48.6% | ||
| Q4 24 | — | 34.6% | ||
| Q3 24 | — | 40.2% | ||
| Q2 24 | — | 26.2% |
资本支出强度CTOSUTHR
| Q1 26 | — | — | ||
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 26.3% | ||
| Q2 25 | — | 7.8% | ||
| Q1 25 | — | 9.4% | ||
| Q4 24 | — | 11.8% | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 6.3% |
现金转化率CTOSUTHR
| Q1 26 | — | — | ||
| Q4 25 | 2.27× | 0.95× | ||
| Q3 25 | — | 1.66× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | 2.98× | 1.13× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 0.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTOS
| Equipment sales | $292.6M | 63% |
| Rental revenue | $137.2M | 30% |
| Parts sales and services | $31.8M | 7% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
